What made the most noise at the 23rd IMS Annual Meeting? Peter Voorhees, MD; Gurbakhash Kaur, MD; C. Ola Landgren, MD, PhD; and Hans Lee, MD, break down the most important data and themes to emerge from #IMS26

Sign up and read more: www.onclive.com/view/etentam...

Curious about highlights from #IMS26?

We spoke with our advisory board member, Rahul Banerjee, MD, about his takeaways from this year's meeting including the MajesTEC-3 & CERVINO clinical trials! #MultipleMyeloma

Check them out here: https://bit.ly/3TfcB7m

Fixed-duration linvoseltamab therapy yielded a 100% ORR & prevented progression to active disease, with a manageable safety profile, in patients with high-risk smoldering #MultipleMyeloma!

From the updated phase 2 LINKER-SMM1 study presented at #IMS26

🔗 Read more: https://bit.ly/4hnw8M7

Hans Lee, MD, @scri.com, talks about the new IMS/IMWG consensus on cure in myeloma from #IMS26 www.targetedonc.com/view/hans-le...

CCTG poster presentations at #IMS26 in Glasgow, Scotland 🏴󠁧󠁢󠁳󠁣󠁴󠁿 ! Dr. Annette Hay with the TACtful Trial poster and Dr. Florenica Comelles presents the MY13 trials in progress abstract poster (Study Chair Dr. Hira Mian)

🚨 Conference update: Catch up with the final day of #IMS26 highlights www.targetedonc.com/view/ims-202...

Don't forget, you can still access #IMS26 meeting content. If you registered for either in-person or virtual this year, log in to the virtual platform to review all recorded sessions. ➡️https://ow.ly/PWuQ50ZRv4p

Thank you to everyone who joined #IMS26, both in person and virtually. Save the date for next year’s meeting, taking place September 29–October 2 in New Delhi, India. We look forward to seeing you in 2027!

Day 4 highlights from the 23rd IMS Annual Meeting! #IMS26

Two new standards of care were established from data shared at #IMS26, Iber-Dara-dex and Etentamig --- Hira Mian, MD, said. She added, the IMS Annual Meeting is already the "It" event for myeloma.

Marc Raab, MD, discussed cure in the context of the GEM14MAIN & MajesTEC-5 data shared during #IMS26. He also summarized studies on improving CAR-T safety and monitoring/managing bone disease during the Highlights session.

Dr. Lawrence Boise’s summary of basic research at #IMS26 included a deep learning classifier for malignant plasma cells, whole proteomics insights into IMiD/CELMoD resistance, an AI-designed trispecific & transmitophagy in MM cells.

There is a BCMA therapy for everyone, whether that be a CAR-T, a bispecific, or an ADC - there is an evidence gap around optimal sequencing and risk/molecular profile-based personalization of these therapies. --- Debate Session at #IMS26

Severity of IEC-Parkinsonism was reduced, although overall incidence rate of delayed neurotoxicities & peak ALC expansion after cilta-cel unchanged w/ prophylactic cyclophosphamide, per observational study shared by Christoph Schaefers, MD #IMS26

Benjamin Puliafito, MD, shares data for elranatamab as fixed-duration consolidative therapy after ide-cel in ph2 EPIC trial.12-month PFS was 94%, elranatamab deepened and prolonged duration of response. #IMS26

At 2:00 PM in Hall 5: Highlights of the 2026 Annual Meeting, followed by the Closing Ceremony. #IMS26

Saurabh Patel, MD, reviews structure & MOA of investigational BCMA×CD28×CD3 trispecific ABBV-2001, which showed efficacy in difficult-to-treat pt subgroups in early-phase clinical trial. #IMS26

Read the recently updated Myeloma Collection, showcasing impactful articles published in Blood Cancer Discovery: buff.ly/CnLyN2M #IMS26

Priyanka Nair-Gupta, PhD, speaks about investigational D-domain BCMA CAR-T anito-cel. Early efficacy and safety of anito-cel in pivotal ph2 iMMagine-1 trial supports further exploration of anito-cel in ph2/3 trails in RRMM, NDMM. #IMS26

Shari Kaiser, PhD, presents rationale, CAR design approach, preclinical efficacy data & examples of clinical response data in pts with diverse target profiles for investigational BCMA/GPRC5d dual-targeting CAR-T, BMS-986453. #IMS26